DOJ, Elevance Health Spar Over Access to Outgoing Medicare Advantage Executive in $40B Fraud Case

The Department of Justice is facing resistance from Elevance Health in its effort to depose a departing executive at the center of one of the largest Medicare Advantage fraud investigations in recent memory.

DOJ attorneys disclosed this week that Elevance Health is blocking access to Peter Haytaian, the former head of the insurer's Medicare Advantage operations, whose exit was announced shortly after authorities first requested his deposition. The timing of Haytaian's departure has drawn scrutiny from prosecutors, who argue the move complicates their ability to secure testimony from a witness with direct knowledge of the practices under investigation. The case, which the DOJ initiated in 2020, centers on allegations that Elevance's Medicare Advantage plans improperly inflated patient risk scores to maximize reimbursement from the federal government. Haytaian previously oversaw the segment that generated more than $40 billion in revenue last year alone, making him a potentially critical witness.

The dispute underscores the high stakes surrounding Elevance's private Medicare plans for seniors, which face wide-ranging regulatory scrutiny beyond the fraud case itself. The company has denied any wrongdoing and maintains its practices comply with federal guidelines. Legal observers note that the government's push to depose Haytaian before his departure suggests prosecutors believe they can establish a direct link between corporate policy and the alleged fraud scheme. Elevance's legal team has argued that Haytaian, as a former employee, is not subject to the same discovery obligations as current executives. The outcome of this standoff could set an important precedent for how federal investigators pursue testimony from executives who leave during active investigations, particularly in cases involving Medicare billing practices that have become a focus of enforcement efforts across the insurance industry.